|
| Press Releases |
|
 |
|
| Tuesday, April 1, 2025 |
|
|
Eisai to Divest Rights for Pariet in China to Peak Pharma |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest the rights for proton pump inhibitor Pariet (generic name: rabeprazole sodium) in China to Beijing Peak Biology Pharmaceuticals Co., Ltd., a CBC Group-controlled company. more info >> |
|
| Tuesday, March 25, 2025 |
|
|
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards |
| Eisai Co., Ltd. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of early Alzheimer's disease (early AD ) has received the Prime Minister's Award at the 12th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society (JATES). more info >> |
|
|
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace |
| Eisai Co., Ltd. announced today that it has been selected by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as a Nadeshiko Brand 2025 as a listed company excelling in the promotion of women in the workplace. more info >> |
|
| Monday, March 10, 2025 |
|
|
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time |
| Eisai Co., Ltd. announced today that it has been recognized as the 2025 KENKO Investment for Health by Japan's Ministry of Economy, Trade, and Industry (METI) and the Tokyo Stock Exchange, for the first time as a company strategically carrying out efforts with regard to its employees' health from a management perspective. more info >> |
|
| Wednesday, March 5, 2025 |
|
|
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan |
| Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced today that they will conclude their co-promotion based on the co-promotion agreement in Japan regarding the orally-administered antifungal agent NAILIN Capsules 100 mg (generic name: fosravuconazole) which is manufactured and marketed by Sato Pharmaceutical, as of March 31, 2025. more info >> |
|
| Tuesday, March 4, 2025 |
|
|
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia has confirmed the initial decision to decline the approval of humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody lecanemab (generic name) as a treatment for early Alzheimer's disease (AD) (mild cognitive impairment due to AD and mild AD dementia). more info >> |
|
| Monday, March 3, 2025 |
|
|
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell" |
| Eisai Co., Ltd. announced today the launch of the new nutritional drink "Chocola BB Nightwell" (designated quasi-drug product), a nutritional drink to help recovery from the accumulated fatigue of the day during sleep, on Monday, March 3. more info >> |
|
|
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti-Abeta; monoclonal antibody lecanemab, adopted in November 2024. more info >> |
|
| Friday, February 28, 2025 |
|
|
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone |
| Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions and continue to manufacture and market it in Japan, where it has been already launched. more info >> |
|
| Thursday, February 20, 2025 |
|
|
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives |
| Eisai Co., Ltd. announced today that it has been selected for "Human CapitalLeaders 2024" and "Human Capital Management Gold Quality" in the "Human Capital Survey 2024" jointly conducted by HR Technology Consortium, HR Research Institute (ProFuture Inc.), MS&AD InterRisk Research & Consulting, Inc. and Association to Confirm the Human Investment Value for Enterprise. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion
Dec 12, 2025 23:15 JST
|
|
|
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
Dec 12, 2025 14:35 HKT/SGT
|
|
|
Anime Tokyo Station: A Series of Linked Events to Be Held in Conjunction with the Anniversary Joint Exhibition
Dec 12, 2025 11:00 JST
|
|
|
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China
Dec 11, 2025 20:00 HKT/SGT
|
|
|
Focus Graphite Achieves 99.9996 wt.% Ultra-High Purity and 2.03 ppm EBC in Follow-On Testing
Dec 11, 2025 18:09 HKT/SGT
|
|
|
Nasdaq Verafin Joins Global Anti-Scam Alliance
Dec 11, 2025 14:21 HKT/SGT
|
|
|
Dr. Teck Lim Chia, Chairman and CEO of CBL International, Honored at the Prestigious Directors of the Year Awards
Dec 11, 2025 12:54 HKT/SGT
|
|
|
Cloudbreak Pharma Soars 80%+ on Multiple Catalysts, Driving Value Re-Rating
Dec 11, 2025 08:20 HKT/SGT
|
|
|
Indonesian Government's Swift Response in Recovering Flood-hit Sumatra
Dec 10, 2025 23:30 HKT/SGT
|
|
|
TIS Helps Treasury Teams Navigate the Ongoing ISO 20022 Transition After the 2025 Banking Deadline
Dec 10, 2025 21:00 HKT/SGT
|
|
|
'M' Mark Event - HKGX 2025 IBF World Championships 
Dec 10, 2025 15:58 HKT/SGT
|
|
|
HKiNEDA Annual Conference Successfully Concludes
Dec 10, 2025 15:11 HKT/SGT
|
|
|
Redefining Global Legal Services with Digital Intelligence China Entercom Empowers Yingke Law Firm to Win 2025 IDC China Future Enterprise Awards
Dec 10, 2025 14:37 HKT/SGT
|
|
|
Trio AI Partners with AbbyPay, a Member of PCG, to Pioneer the Future of AI-Powered Payments
Dec 10, 2025 12:12 HKT/SGT
|
|
|
Majority of Australian Parents (65%) and U.S. Parents 58% Support Social Media Ban for Under 16s, but Kids Say It Risks Cutting Them Off from Key Connections
Dec 9, 2025 22:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
